Live Breaking News & Updates on கெவன் ஷோகாட்

Stay updated with breaking news from கெவன் ஷோகாட். Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Precision oncology outfit Erasca joins the parade of San Diego IPOs this year


Print
Erasca, a biotechnology company pursuing precision oncology treatments to “erase cancer,” became San Diego’s newest publicly traded company late last week, raising $300 million in an upsized initial public stock offering.
The company, co-founded in 2018 by life sciences entrepreneur Dr. Jonathan Lim, becomes the 11
th local firm to go public so far this year. That’s approaching an annual record of 12 IPOs on U.S. markets for San Diego-based startups with five months to go in 2021.
Erasca sold 18.75 million shares at $16 per share. The stock began trading Friday on the Nasdaq exchange.
The company is targeting certain cancer-causing gene mutations. These mutations create a form of protein that continually tells cancer cells that it is okay to multiply. ....

San Diego , United States , Roche Genentech , Kevan Shokat , Jonathan Lim , San Diego Based , Halozyme Therapeutics , Eclipse Therapeutics , சான் டியாகோ , ஒன்றுபட்டது மாநிலங்களில் , ரோச் ஜெநிஂடெக் , கெவன் ஷோகாட் , ஜொனாதன் லிம் , சான் டியாகோ அடிப்படையிலானது , கிரகணம் சிகிச்சை ,

Tumors find many ways to evade groundbreaking cancer drug


Share
Patients with lung cancer (shown here) developed a wide array of resistance mechanisms to a KRAS inhibitor drug.
SPL/Science Source
Tumors find many ways to evade groundbreaking cancer drug
Jun. 23, 2021 , 5:45 PM
Researchers were ecstatic 2 years ago when, after decades of effort, they devised drugs that could block a tumor-promoting protein in cancer patients called KRAS, which previously seemed impervious to treatment. But many of these KRAS inhibitors the first of which was approved by U.S. regulators in May quickly lost their luster, like other targeted cancer drugs: Most patients’ tumors resumed growing after a few months, as their cancer cells became resistant to the inhibitors. Now, a study finds that the roots of this resistance are surprisingly complex, with tumors using an array of escape routes to evade the attack on KRAS. ....

United States , San Francisco , Mark Awad , Kevan Shokat , Andrew Aguirre , Jocelyn Kaiser , Colin Lindsay , University Of California , University Of Manchester , Dana Farber Cancer Institute , Science Source , New England Journal , ஒன்றுபட்டது மாநிலங்களில் , சான் பிரான்சிஸ்கோ , குறி அவாட் , கெவன் ஷோகாட் , ஜாஸ்லைந் கைசர் , கொலின் லிண்ட்சே , பல்கலைக்கழகம் ஆஃப் கலிஃபோர்னியா , பல்கலைக்கழகம் ஆஃப் மான்செஸ்டர் , டானா ஃபார்‌பர் புற்றுநோய் நிறுவனம் , அறிவியல் மூல , புதியது இங்கிலாந்து இதழ் ,